CapitalBio Technology’s medical equipment wins the gold award in the Innovation Star Cup Awards Ceremony for Excellent Equipment for Experimental Medicine of China on Mar 21.

Thermostatically amplified microfluidic nucleic acid analyzer equipment 

Medical equipment of CapitalBio Technology, affiliated to CapitalBio Corporation under Tsinghua Holdings, won the gold award for in-vitro diagnosis innovation at an experimental medicine awards ceremony on Mar 21.

The thermostatically amplified micro fluidic nucleic acid analyzer of CapitalBio Technology was awarded for outstanding innovation of in-vitro diagnosis in 2018.

It can quickly realize molecular replication and amplification and specific sequence molecular fragment complementary matching which leads to fast and precise authentication of pathogenic bacteria on the molecular level.

Together with relevant software, reagents and consumables developed independently by CapitalBio, the analyzer can help test multiple common pathogenic bacteria in respiratory secretions rapidly and parallely, solving such problems as the need for a long detection period, low diagnosis rates and difficult bacterial culturing.

The analyzer has already been used in several fields such as life science basic research, food safety and inspection quarantines.

The situation of empirical pharmacy in diagnosis and treatment of respiratory infection is changing thanks to the analyzer. Since its development, the detection of respiratory pathogens has become precise in China. It has been used in more than 300 hospitals and research institutes across China such as Peking University People’s Hospital, Peking Union Medical College Hospital andthe Guangzhou Institute of Respiratory Health, saving the lives of many critically ill patients.